IJMS | Free Full-Text | A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy
Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell... | Oncotarget
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC - ScienceDirect
Sunitinib re-challenge in advanced renal-cell carcinoma | British Journal of Cancer
a) Progression-free survival (PFS) in 90 mRCC patients treated with... | Download Scientific Diagram
Overall Survival in Renal-Cell Carcinoma with Pazopanib versus Sunitinib | NEJM
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response ...
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
New Data on KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus Sunitinib in First-Line Treatment for Patients With Advanced Renal Cell Carcinoma From Pivotal Phase 3 CLEAR/KEYNOTE-581 Trial Presented at 2021 ASCO Annual Meeting
Progression-free survival (a) and overall survival (b) of patients... | Download Scientific Diagram
Frontiers | Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First- Line Setting
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Overall survival for first-line IO combination therapies. CI =... | Download Scientific Diagram
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma | NEJM
Frontiers | Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China
Identification of low-dose multidrug combinations for sunitinib-naive and pre-treated renal cell carcinoma | British Journal of Cancer
Sunitinib - Wikipedia
Overall Survival. (A) OS, (B) Kaplan-Meier Curve for OS From First Line... | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma | Anticancer Research
Cancers | Free Full-Text | Progression-Free and Overall Survival of First- Line Treatments for Advanced Renal Cell Carcinoma: Indirect Comparison of Six Combination Regimens
Adjuvant Sunitinib Prolongs Disease-free Survival in High-risk RCC Post-nephrectomy - Cancer Therapy Advisor
Overall survival rates of advanced gastrointestinal stromal tumor... | Download Scientific Diagram
Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma | Future Oncology
